AU2002311445B2 - Arylazo-substituted imidazole for the treatment of stress urinary incontinence - Google Patents
Arylazo-substituted imidazole for the treatment of stress urinary incontinence Download PDFInfo
- Publication number
- AU2002311445B2 AU2002311445B2 AU2002311445A AU2002311445A AU2002311445B2 AU 2002311445 B2 AU2002311445 B2 AU 2002311445B2 AU 2002311445 A AU2002311445 A AU 2002311445A AU 2002311445 A AU2002311445 A AU 2002311445A AU 2002311445 B2 AU2002311445 B2 AU 2002311445B2
- Authority
- AU
- Australia
- Prior art keywords
- imidazole
- arylazo
- urinary incontinence
- azo
- stress urinary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title claims description 29
- 206010066218 Stress Urinary Incontinence Diseases 0.000 title claims description 10
- 150000002460 imidazoles Chemical class 0.000 title claims description 8
- IXQGZPLNCYHNKT-UHFFFAOYSA-N chembl1435053 Chemical group COC1=CC=C(Cl)C=C1N=NC1=NC=CN1 IXQGZPLNCYHNKT-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 9
- 230000001800 adrenalinergic effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 description 15
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 13
- 229960002748 norepinephrine Drugs 0.000 description 13
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 230000004044 response Effects 0.000 description 8
- 239000000556 agonist Substances 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000003975 mesenteric artery Anatomy 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000004031 partial agonist Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- -1 troches Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- OQIIGZDXXJHFOW-UHFFFAOYSA-N 1H-imidazol-2-yl-(2-methoxyphenyl)diazene Chemical class COC1=CC=CC=C1N=NC1=NC=CN1 OQIIGZDXXJHFOW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000002163 alpha 1-adrenoceptor agonist Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0114008.6 | 2001-06-08 | ||
| GBGB0114008.6A GB0114008D0 (en) | 2001-06-08 | 2001-06-08 | New therapautic use |
| PCT/GB2002/002635 WO2002100414A1 (en) | 2001-06-08 | 2002-06-07 | Arylazo-substituted imidazole for the treatment of stress urinary incontinence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002311445A1 AU2002311445A1 (en) | 2003-05-15 |
| AU2002311445B2 true AU2002311445B2 (en) | 2005-08-25 |
Family
ID=9916211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002311445A Ceased AU2002311445B2 (en) | 2001-06-08 | 2002-06-07 | Arylazo-substituted imidazole for the treatment of stress urinary incontinence |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040242547A1 (https=) |
| EP (1) | EP1399167A1 (https=) |
| JP (1) | JP2005500285A (https=) |
| KR (1) | KR20040030654A (https=) |
| CN (1) | CN1234367C (https=) |
| AU (1) | AU2002311445B2 (https=) |
| BR (1) | BR0210195A (https=) |
| CA (1) | CA2449957A1 (https=) |
| GB (1) | GB0114008D0 (https=) |
| MX (1) | MXPA03011226A (https=) |
| RU (1) | RU2004100228A (https=) |
| WO (1) | WO2002100414A1 (https=) |
| ZA (1) | ZA200309473B (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6056123B2 (ja) * | 1979-07-30 | 1985-12-09 | 持田製薬株式会社 | 浮腫・低血圧・心不全および粘膜充血治療用剤 |
| DE19514579A1 (de) * | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
| US6323231B1 (en) * | 2000-02-17 | 2001-11-27 | Abbott Laboratories | Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence |
-
2001
- 2001-06-08 GB GBGB0114008.6A patent/GB0114008D0/en not_active Ceased
-
2002
- 2002-06-07 KR KR10-2003-7015978A patent/KR20040030654A/ko not_active Withdrawn
- 2002-06-07 EP EP02738362A patent/EP1399167A1/en not_active Withdrawn
- 2002-06-07 ZA ZA200309473A patent/ZA200309473B/xx unknown
- 2002-06-07 CA CA002449957A patent/CA2449957A1/en not_active Abandoned
- 2002-06-07 CN CNB028129687A patent/CN1234367C/zh not_active Expired - Fee Related
- 2002-06-07 US US10/478,977 patent/US20040242547A1/en not_active Abandoned
- 2002-06-07 AU AU2002311445A patent/AU2002311445B2/en not_active Ceased
- 2002-06-07 JP JP2003503235A patent/JP2005500285A/ja not_active Withdrawn
- 2002-06-07 WO PCT/GB2002/002635 patent/WO2002100414A1/en not_active Ceased
- 2002-06-07 RU RU2004100228/15A patent/RU2004100228A/ru not_active Application Discontinuation
- 2002-06-07 BR BR0210195-5A patent/BR0210195A/pt not_active IP Right Cessation
- 2002-06-07 MX MXPA03011226A patent/MXPA03011226A/es unknown
Non-Patent Citations (1)
| Title |
|---|
| References cited in WO02/100414 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1234367C (zh) | 2006-01-04 |
| MXPA03011226A (es) | 2004-03-26 |
| CN1541099A (zh) | 2004-10-27 |
| US20040242547A1 (en) | 2004-12-02 |
| KR20040030654A (ko) | 2004-04-09 |
| GB0114008D0 (en) | 2001-08-01 |
| ZA200309473B (en) | 2005-03-23 |
| BR0210195A (pt) | 2004-07-27 |
| JP2005500285A (ja) | 2005-01-06 |
| RU2004100228A (ru) | 2005-06-10 |
| EP1399167A1 (en) | 2004-03-24 |
| WO2002100414A1 (en) | 2002-12-19 |
| CA2449957A1 (en) | 2002-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morgan et al. | Effects of interstrain renal transplantation on NaCl-induced hypertension in Dahl rats. | |
| CA2219502C (en) | Methods and formulations for modulating the human sexual response | |
| CN1617715B (zh) | 用雄激素受体选择性调节剂治疗肌消耗 | |
| RU2310443C2 (ru) | Синергетические композиции, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний | |
| KR101529541B1 (ko) | 고양이에서 전신성 질환을 치료하기 위한 안지오텐신 ｉｉ 수용체 길항제 | |
| KR20010023498A (ko) | 아믈로디핀 및 아토르바스타틴을 함유하는 치료적 배합물 | |
| Biaggioni et al. | Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure | |
| JP4048024B2 (ja) | 新規経口製剤 | |
| HU229150B1 (hu) | Gyorsan ható szelektív szerotonin-újrafelvételt gátlókat alkalmazó eljárások nemi mûködési zavarok kezelésére | |
| CH691847A5 (fr) | Utilisation de raloxifène dans la prophylaxie du cancer du sein. | |
| Schoeffter et al. | Modulatory role of the vascular endothelium in the contractility of human isolated internal mammary artery | |
| JP4685201B2 (ja) | 頻尿および尿失禁の予防・治療剤 | |
| AU2002311445B2 (en) | Arylazo-substituted imidazole for the treatment of stress urinary incontinence | |
| CA2167257C (en) | Use of sertraline to treat cancer patients | |
| Keaton et al. | Captopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive rat | |
| AU2002311445A1 (en) | Arylazo-substituted imidazole for the treatment of stress urinary incontinence | |
| WO1997019700A1 (en) | Novel drug for relieving pain and promoting the removal of calculi in urolithiasis | |
| De Clerck et al. | Correction by ketanserin of the platelet‐mediated inhibition of peripheral collateral circulation in the cat: Measurement of blood flow with radioactive microspheres | |
| JPH0680009B2 (ja) | 抗高血圧組み合わせ医薬 | |
| Rizzi et al. | Antagonistic effects of FR 173657 on human, pig, rabbit, and guinea pig kinin receptors: an in vitro study | |
| Movahedi et al. | Effect of alpha adrenergic agonist on the rabbit ear artery contraction to serotonin: Enhanced response mediated by serotonergic1-like receptors. | |
| Tamura et al. | Temporal regression of myocyte hypertrophy in hypertensive, heart failure–prone rats treated with an AT1-receptor antagonist | |
| Spadari-Bratfisch et al. | Pharmacological evidence for β2-adrenoceptor in right atria from stressed female rats | |
| JP2007513865A (ja) | 前立腺癌を処置および予防するベンゾジオフェンの使用 | |
| Yan et al. | Tyrosine kinase inhibitors suppress α1-adrenoceptor mediated contraction in human radial, internal mammary arteries and saphenous vein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ARACHNOVA THERAPEUTICS LTD.; SOSEI CO. LTD Free format text: FORMER APPLICANT(S): PERRY, ROBERT EDWARD |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |